Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 1
2021 2
2022 3
2023 1
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for orphan disease treatment institute of., Ltd.[Grants and Funding]
Your search for Orphan Disease Treatment Institute Co., Ltd.[Grants and Funding] retrieved no results
Zinpentraxin Alfa for Idiopathic Pulmonary Fibrosis: The Randomized Phase III STARSCAPE Trial.
Richeldi L, Schiffman C, Behr J, Inoue Y, Corte TJ, Cottin V, Jenkins RG, Nathan SD, Raghu G, Walsh SLF, Jayia PK, Kamath N, Martinez FJ. Richeldi L, et al. Am J Respir Crit Care Med. 2024 May 1;209(9):1132-1140. doi: 10.1164/rccm.202401-0116OC. Am J Respir Crit Care Med. 2024. PMID: 38354066 Clinical Trial.
The trial was terminated early after a prespecified futility analysis that demonstrated no treatment benefit of zinpentraxin alfa over placebo. In the final analysis, absolute change from baseline to Week 52 in FVC was similar between placebo and zinpentraxin alfa (-214.89 …
The trial was terminated early after a prespecified futility analysis that demonstrated no treatment benefit of zinpentraxin alfa ove …
Association Between T2-related Comorbidities and Effectiveness of Biologics in Severe Asthma.
Wechsler ME, Scelo G, Larenas-Linnemann DES, Torres-Duque CA, Maspero J, Tran TN, Murray RB, Martin N, Menzies-Gow AN, Hew M, Peters MJ, Gibson PG, Christoff GC, Popov TA, Côté A, Bergeron C, Dorscheid D, FitzGerald JM, Chapman KR, Boulet LP, Bhutani M, Sadatsafavi M, Jiménez-Maldonado L, Duran-Silva M, Rodriguez B, Celis-Preciado CA, Cano-Rosales DJ, Solarte I, Fernandez-Sanchez MJ, Parada-Tovar P, von Bülow A, Bjerrum AS, Ulrik CS, Assing KD, Rasmussen LM, Hansen S, Altraja A, Bourdin A, Taille C, Charriot J, Roche N, Papaioannou AI, Kostikas K, Papadopoulos NG, Salvi S, Long D, Mitchell PD, Costello R, Sirena C, Cardini C, Heffler E, Puggioni F, Canonica GW, Guida G, Iwanaga T, Al-Ahmad M, García U, Kuna P, Fonseca JA, Al-Lehebi R, Koh MS, Rhee CK, Cosio BG, Perez de Llano L, Perng DS, Huang EW, Wang HC, Tsai MJ, Mahboub B, Salameh LIJ, Jackson DJ, Busby J, Heaney LG, Pfeffer PE, Goddard AG, Wang E, Hoyte FCL, Chapman NM, Katial R, Carter V, Bulathsinhala L, Eleangovan N, Ariti C, Lyu J, Porsbjerg C, Price DB. Wechsler ME, et al. Am J Respir Crit Care Med. 2024 Feb 1;209(3):262-272. doi: 10.1164/rccm.202305-0808OC. Am J Respir Crit Care Med. 2024. PMID: 38016003

However, patients with comorbid CRS with or without NPs experienced 23% fewer exacerbations per year (95% CI, 10-35%; P < 0.001) and had 59% higher odds of better post-biologic therapy asthma control (95% CI, 26-102%; P < 0.001) than those without CRS with or without

…

However, patients with comorbid CRS with or without NPs experienced 23% fewer exacerbations per year (95% CI, 10-35%; P < 0.001) and had

…
Attention challenges in Kabuki syndrome.
Kalinousky AJ, Rapp T, Harris JR. Kalinousky AJ, et al. J Intellect Disabil Res. 2024 Feb;68(2):173-180. doi: 10.1111/jir.13100. Epub 2023 Nov 3. J Intellect Disabil Res. 2024. PMID: 37921399
BACKGROUND: Understanding the specific neurobehavioural profile of rare genetic diseases enables clinicians to provide the best possible care for patients and families, including prognostic and treatment advisement. ...
BACKGROUND: Understanding the specific neurobehavioural profile of rare genetic diseases enables clinicians to provide the bes …
Liposomal amphotericin B-the future.
Hoenigl M, Lewis R, van de Veerdonk FL, Verweij PE, Cornely OA. Hoenigl M, et al. J Antimicrob Chemother. 2022 Nov 25;77(Suppl_2):ii21-ii34. doi: 10.1093/jac/dkac353. J Antimicrob Chemother. 2022. PMID: 36426674 Free PMC article.
Consideration must also be given to the risk of drug-drug interactions between mould-active azoles and small-molecule kinase inhibitors. At the same time, infections caused by rare moulds and yeasts are increasing, and diagnosis continues to be challenging. ...Early diagno …
Consideration must also be given to the risk of drug-drug interactions between mould-active azoles and small-molecule kinase inhibitors. At …
Tumor Treating Fields Concomitant with Sorafenib in Advanced Hepatocellular Cancer: Results of the HEPANOVA Phase II Study.
Gkika E, Grosu AL, Macarulla Mercade T, Cubillo Gracián A, Brunner TB, Schultheiß M, Pazgan-Simon M, Seufferlein T, Touchefeu Y. Gkika E, et al. Cancers (Basel). 2022 Mar 18;14(6):1568. doi: 10.3390/cancers14061568. Cancers (Basel). 2022. PMID: 35326718 Free PMC article.
Advanced hepatocellular carcinoma (HCC) is an aggressive disease associated with poor prognosis. Tumor Treating Fields (TTFields) therapy is a non-invasive, loco-regional treatment approved for glioblastoma and malignant pleural mesothelioma. ...Patients rece …
Advanced hepatocellular carcinoma (HCC) is an aggressive disease associated with poor prognosis. Tumor Treating Fields (TTFields) …
Phase 2 study of avatrombopag in Japanese patients with chronic liver disease and thrombocytopenia.
Eguchi Y, Takahashi H, Mappa S, Santagostino E. Eguchi Y, et al. Hepatol Res. 2022 Apr;52(4):371-380. doi: 10.1111/hepr.13755. Epub 2022 Feb 21. Hepatol Res. 2022. PMID: 35134259
AIM: Avatrombopag, a thrombopoietin receptor agonist, can reduce the need for platelet transfusions or rescue interventions for bleeding in patients with chronic liver disease (CLD) and thrombocytopenia undergoing scheduled procedures. ...The primary endpoint was responder …
AIM: Avatrombopag, a thrombopoietin receptor agonist, can reduce the need for platelet transfusions or rescue interventions for bleeding in …
Renadirsen, a Novel 2'OMeRNA/ENA® Chimera Antisense Oligonucleotide, Induces Robust Exon 45 Skipping for Dystrophin In Vivo.
Ito K, Takakusa H, Kakuta M, Kanda A, Takagi N, Nagase H, Watanabe N, Asano D, Goda R, Masuda T, Nakamura A, Onishi Y, Onoda T, Koizumi M, Takeshima Y, Matsuo M, Takaishi K. Ito K, et al. Curr Issues Mol Biol. 2021 Sep 25;43(3):1267-1281. doi: 10.3390/cimb43030090. Curr Issues Mol Biol. 2021. PMID: 34698059 Free PMC article.
Duchenne muscular dystrophy (DMD) is a progressive muscle-wasting disease caused by out-of-frame or nonsense mutation in the dystrophin gene. ...
Duchenne muscular dystrophy (DMD) is a progressive muscle-wasting disease caused by out-of-frame or nonsense mutation in the dystroph …
Treatment and relapse of interstitial lung disease in nivolumab-treated patients with non-small cell lung cancer.
Sata M, Sasaki S, Oikado K, Saito Y, Tominaga J, Sakai F, Kato T, Iwasawa T, Kenmotsu H, Kusumoto M, Baba T, Endo M, Fujiwara Y, Sugiura H, Yanagawa N, Ito Y, Sakamoto T, Ohe Y, Kuwano K. Sata M, et al. Cancer Sci. 2021 Apr;112(4):1506-1513. doi: 10.1111/cas.14715. Epub 2021 Feb 24. Cancer Sci. 2021. PMID: 33125784 Free PMC article.
Nivolumab, a human monoclonal antibody against programmed death-1, is approved for the treatment of non-small cell lung cancer (NSCLC). Although nivolumab is generally well tolerated, it can cause interstitial lung disease (ILD), a rare but potentially fatal …
Nivolumab, a human monoclonal antibody against programmed death-1, is approved for the treatment of non-small cell lung cancer (NSCLC …
Clinical characteristics and outcomes of invasive Lomentospora prolificans infections: Analysis of patients in the FungiScope® registry.
Jenks JD, Seidel D, Cornely OA, Chen S, van Hal S, Kauffman C, Miceli MH, Heinemann M, Christner M, Jover Sáenz A, Burchardt A, Kemmerling B, Herbrecht R, Steinmann J, Shoham S, Gräber S, Pagano L, Deeren D, Slavin MA, Hoenigl M. Jenks JD, et al. Mycoses. 2020 May;63(5):437-442. doi: 10.1111/myc.13067. Epub 2020 Apr 15. Mycoses. 2020. PMID: 32080902 Free article.
Most infections (59%) were breakthrough infections. Progression/deterioration/treatment failure was observed in 23/40 (58%) of patients receiving antifungal therapy. ...In particular, treatment regimens including terbinafine were significantly associated with …
Most infections (59%) were breakthrough infections. Progression/deterioration/treatment failure was observed in 23/40 (58%) of patien …
Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis.
Costabel U, Albera C, Glassberg MK, Lancaster LH, Wuyts WA, Petzinger U, Gilberg F, Kirchgaessler KU, Noble PW. Costabel U, et al. Respir Res. 2019 Mar 12;20(1):55. doi: 10.1186/s12931-019-1021-2. Respir Res. 2019. PMID: 30866942 Free PMC article. Clinical Trial.
Patients were categorised according to the extent of lung function impairment at baseline: more advanced (percent predicted FVC <50% and/or DLco <35%) and less advanced (percent predicted FVC 50% and DLco 35%).Overall, 596 patients with baseline FVC and/or DLco values avail …
Patients were categorised according to the extent of lung function impairment at baseline: more advanced (percent predicted FVC <50% and/ …